iRadimed Corporation $IRMD Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. trimmed its stake in shares of iRadimed Corporation (NASDAQ:IRMD) by 1.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 560,048 shares of the medical equipment provider’s stock after selling 6,459 shares during the quarter. Vanguard Group Inc. owned about 4.40% of iRadimed worth $54,481,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Arizona State Retirement System acquired a new stake in shares of iRadimed during the 4th quarter worth approximately $225,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of iRadimed by 4.8% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,824 shares of the medical equipment provider’s stock worth $567,000 after purchasing an additional 267 shares during the period. CWM LLC raised its position in shares of iRadimed by 19.5% during the 4th quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock worth $64,000 after purchasing an additional 107 shares during the period. Farther Finance Advisors LLC raised its position in shares of iRadimed by 827.1% during the 4th quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 397 shares during the period. Finally, State of Alaska Department of Revenue raised its position in shares of iRadimed by 187.4% during the 4th quarter. State of Alaska Department of Revenue now owns 1,900 shares of the medical equipment provider’s stock worth $184,000 after purchasing an additional 1,239 shares during the period. 92.34% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Roger E. Susi sold 4,411 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $83.92, for a total value of $370,171.12. Following the sale, the chief executive officer directly owned 2,180,000 shares in the company, valued at $182,945,600. This trade represents a 0.20% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 60,000 shares of company stock valued at $5,661,603. 36.80% of the stock is owned by company insiders.

iRadimed Price Performance

IRMD opened at $86.44 on Friday. iRadimed Corporation has a 12 month low of $50.88 and a 12 month high of $107.90. The stock has a market cap of $1.10 billion, a P/E ratio of 47.24 and a beta of 0.90. The stock’s 50 day moving average price is $93.68 and its 200 day moving average price is $94.67.

iRadimed (NASDAQ:IRMD) last posted its earnings results on Friday, May 1st. The medical equipment provider reported $0.49 EPS for the quarter, beating the consensus estimate of $0.46 by $0.03. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.The firm had revenue of $21.98 million for the quarter, compared to analysts’ expectations of $21.32 million. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. Equities analysts anticipate that iRadimed Corporation will post 1.52 EPS for the current year.

iRadimed Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 29th. Investors of record on Friday, May 15th will be given a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.9%. The ex-dividend date is Friday, May 15th. iRadimed’s dividend payout ratio (DPR) is currently 43.72%.

Analyst Upgrades and Downgrades

IRMD has been the topic of a number of research reports. Lake Street Capital reiterated a “buy” rating and set a $120.00 price target on shares of iRadimed in a research report on Wednesday, February 11th. Freedom Capital upgraded iRadimed to a “strong-buy” rating in a research report on Thursday, April 2nd. Roth Mkm reiterated a “buy” rating and set a $120.00 price target on shares of iRadimed in a research report on Tuesday, February 10th. Finally, Weiss Ratings upgraded iRadimed from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $120.00.

iRadimed Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.